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ABSTRACT
Objective: To explore people’s experiences of starting
antidepressant treatment.
Design: Qualitative interpretive approach combining
thematic analysis with constant comparison.
Relevant coding reports from the original studies
(generated using NVivo) relating to initial
experiences of antidepressants were explored in
further detail, focusing on the ways in which
participants discussed their experiences of taking
or being prescribed an antidepressant for the first
time.
Participants: 108 men and women aged 22–84 who
had taken antidepressants for depression.
Setting: Respondents recruited throughout the UK
during 2003–2004 and 2008 and 2012–2013 and in
Australia during 2010–2011.
Results: People expressed a wide range of feelings
about initiating antidepressant use. People’s attitudes
towards starting antidepressant use were shaped by
stereotypes and stigmas related to perceived drug
dependency and potentially extreme side effects.
Anxieties were expressed about starting use, and
about how long the antidepressant might begin to take
effect, how much it might help or hinder them, and
about what to expect in the initial weeks. People
worried about the possibility of experiencing adverse
effects and implications for their senses of self. Where
people felt they had not been given sufficient time
during their consultation information or support to
take the medicines, the uncertainty could be
particularly unsettling and impact on their ongoing
views on and use of antidepressants as a viable
treatment option.
Conclusions: Our paper is the first to explore
in-depth patient existential concerns about start of
antidepressant use using multicountry data. People
need additional support when they make decisions
about starting antidepressants. Health professionals
can use our findings to better understand and
explore with patients’ their concerns before their
patients start antidepressants. These insights are
key to supporting patients, many of whom feel
intimidated by the prospect of taking antidepressants,
especially during the uncertain first few weeks of
treatment.
INTRODUCTION
Receiving a prescription for antidepressants
for the ﬁrst time is a signiﬁcant event and
frequently a worrying time for patients.
During a consultation leading to an anti-
depressant prescription, patients may experi-
ence difﬁculty absorbing the information
given,1 and they may hold preconceptions
about the treatment based on their own and
Strengths and limitations of this study
▪ While much has been written about adherence,
compliance, and patient meaning-making in rela-
tion to taking antidepressants over the full
course of treatment, researchers have neglected
the critical period of when patients start treat-
ment with antidepressants.
▪ This paper focuses attention around the time
people experience being given their first anti-
depressant prescription and when they contem-
plate taking their first dose. Our paper seeks to
illuminate patient experiences in a manner that
encourages health professionals to better con-
sider what patients go through explicitly, so that
better decision-making and care in the crucial
early stages of antidepressant treatment can be
advanced.
▪ While our study contributes important informa-
tion, it must be considered in the light of a
number of study limitations. Only people willing
to talk about their depression or taking antide-
pressants were interviewed and many of the par-
ticipants regarded themselves as being in
‘recovery’, and so were doing relatively well.
▪ While the study does not claim numerical repre-
sentation (this is not the purpose of maximum
variation sampling), our sample reveals a wide
range of experience and complexities about
experiences of taking antidepressants in the UK
and Australia.
▪ Full details about individual’s prescribed medi-
cines in this study were not available as they
were not originally collected.
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other people’s beliefs, their past experiences with medi-
cines, and the quality of their relationships with health-
care providers.2 Patients may be concerned about side
effects they might experience well before they experi-
ence any therapeutic effects.3 The extent to which
patients accept their diagnosis and prescription of anti-
depressants at the early point of consultation with health
professionals is critical in determining their ongoing
adherence to medication in the future.4 Factors thought
to explain whether a patient starts or continues to take
antidepressants include: beliefs about illness; resistance
to viewing depression as an illness and the associated
lack of belief about the need for antidepressants; and
concerns about addiction and dependency.5 6 Patients’
resistance to medicines for chronic physical conditions
such as diabetes, hypertension and epilepsy is founded
partially on the threat medication poses to self-
integrity,7 8 and the difﬁculties surrounding acceptance
of medication for psychological disorders involves add-
itional complexities, for example, fears about loss of an
‘authentic’ self.9 10 Equally, if a meaningful decision-
making relationship between practitioners and patients
is routinely difﬁcult,11 12 these and other difﬁculties may
be exacerbated by symptoms of depression, for example,
impaired cognitive ability to engage in decision-
making.13 While much has been written about adher-
ence, compliance and patient meaning-making in rela-
tion to taking antidepressants over the full course of
treatment,14–16 researchers have neglected to examine
in-depth the critical period of start of treatment with
antidepressants.
STUDY DESIGN AND METHODS
This paper combines data from three qualitative
research studies that we conducted in the UK (studies
(1—UKa) and (3—UKb)) and Australia (study (2); total
sample size n=114). We conducted all three studies
using an agreed set of rigorous strategies and guidelines,
based on methods developed by the Health Experience
Research Group (HERG) at Oxford University.17 The
main focus of (1) and (2) was ‘Experiences of depres-
sion’. Interviews were conducted (1—UKa) in the UK in
2003–2004 (n=38) by DR and (2) in Australia in 2010–
2011 (n=40) by RK and colleagues. In (3—UKb) inter-
views were conducted in 2012 in the UK by SK (n=36)
with a speciﬁc focus on ‘Experiences of using antide-
pressants’. For demographic details (age and ethnicity)
please see tables 1.
Ethics approval for the original studies was granted by
Berkshire Research Ethics Committee (multi site recruit-
ment) in the UK, and in Australia by Monash University
Human Research Ethics Committee (MUHREC).
The overall aim of the study was to examine in detail
the ideas about start of antidepressants of a broad
sample of antidepressant users and not to compare UK
and Australian data as treatment is similar in each
country. The combined narrative data from three UK
and Australian narrative data collections provide a rich
source of qualitative data for secondary analysis. Our
paper expands on the original work by focusing solely
on narrative accounts relating to the views, emotions
and experiences of people on start of an antidepressant.
Initial comparisons of the interview data during group
email exchanges revealed similarities across all three
studies, relating to narratives about initial use of an anti-
depressant and the profound impact this may have had
on participants’ ongoing experiences of managing
depression. Our analysis aims to explore these predom-
inant themes and to synthesise similarities and common-
alities in experiences.
The original research
Participants were recruited for the original studies
through a variety of routes including newsletters, web-
sites, support groups, word of mouth and via health prac-
titioners. Each study aimed to capture a wide variation in
experiences and social demographic variables.18 We con-
ducted most interviews in participants’ homes with just
the interviewer and participant present, using a narrative
style with subsequent prompting on topics including
Table 1 Demographic details (age and ethnicity) of
people we interviewed
UKa
(n=38)
UKb
(n=36)
Australia
(n=40)
Age group in years
20–29 3 17 5
30–39 12 15 6
40–49 9 5 13
50–59 8 5 9
60–69 4 1 4
70–79 2 2 3
80–89 0 1 0
Gender
Male 16 13 16
Female 22 23 24
Ethnicity
White British 33 27 1
Anglo Australian 0 0 26
Black 1 0 0
Asian 1 0 0
American 1 0 0
British Indian 0 1
Jewish 0 1 1
British Iranian 0 1
White European 2 1 2
White Irish 0 2
Chinese 0 0 1
European Australian 0 0 2
Hispanic 0 0 1
Malaysian 0 0 1
Rwandan 0 0 1
Vietnamese 0 0 1
Chinese Anglo Australian 0 0 1
Anglo Canadian 0 0 1
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responses to a diagnosis of depression and being pre-
scribed an antidepressant. Initial interviews served as
pilots and the interview guides were pilot tested with the
study advisory groups which included people with
depression. Participants were interviewed until no new
themes arose. The original interviews were conducted in
person by authors DR, RK and SK who are experienced
qualitative researchers, were digitally recorded and tran-
scribed verbatim. Transcripts were returned to partici-
pants for comment and/or correction.
Analysis
Both the original studies, and the analysis for this paper
used a qualitative interpretive approach combining the-
matic analysis with constant comparison.19 20 For this
analysis, CA explored relevant coding reports from the
original studies (generated using NVivo, a qualitative
software package) relating to start of antidepressants in
further detail, focusing on the ways in which participants
discussed their experiences of taking or being pre-
scribed an antidepressant for the ﬁrst time.
By means of an iterative process, data extracts from
the coding reports relating to initiation of medicines
identiﬁed by CA were subsequently discussed and
reviewed jointly by all authors through email exchanges
and online conference calls. In the ﬁnal round of ana-
lysis, CA synthesised the analysis and ﬁndings relating to
participants’ uncertainties, anxieties and concerns about
start of treatment.
FINDINGS
Attitudes to taking antidepressants
Participants expressed a wide range of ideas and feelings
about contemplating taking antidepressants. Some had
few qualms about taking antidepressants, and pragmatic-
ally saw them as a means to an end:
I actually didn’t have an ideological or philosophical pos-
ition about medication. For me medication was a means
to an end. (Catherine, Aus, F, 39)
Although people frequently argued that it was no dif-
ferent to taking medicines for other health conditions,
such as using insulin for diabetes, others reﬂected on
the way antidepressants are considered to be in a differ-
ent class to other medicines:
I don’t put my hands up in horror with psychiatric
drugs…there’s a lot of people turning against them…
they wouldn’t have the same attitude towards insulin or
other drugs that were lifesaving. ( Jean, UKb, F, 71)
Others disliked the ‘mind-altering’ potential of antide-
pressants, or potentially becoming dependent on a
chemical substance to improve their mood. Taking med-
icines that were thought to ‘mess with the mind’ was per-
ceived particularly negatively. This was particularly so
when the reluctance to take antidepressants was tied
into the idea that they might get better without the
medical intervention anyway:
I think taking medication is something I really struggled
with because I didn’t want to take it. I didn’t want to—
you know I thought I could just get better on my own.
(Nicole, Aus, F, 27)
I obviously knew that there was antidepressants available
but they’ve kind of got a stigma and I was worried that I
didn’t want anything I could get addicted to. (Maggie,
UKb, F, 44)
Some people resisted taking antidepressants because
they saw it as a sign of weakness that proved “that some-
thing’s wrong and a lot of people don’t like to admit
that something’s wrong”. Ellie (UKb, F, 30) felt that men
were particularly inclined to see using antidepressants in
this way. Nevertheless, participants felt that the stigma
around taking antidepressants was unjustiﬁed.
People also feared that antidepressants might mask
their problems but not actually resolve it, and that they
should manage it themselves, free of medicines, rather
than ‘papering over the cracks’.
Information
In the past, it was difﬁcult for people to ﬁnd information
about the medicine they were prescribed, but these days
the internet is routinely used by people to look up
health information. People we spoke to in study UKb
and Australia (carried out later than UKa) had routinely
used the internet to ﬁnd information, including about
different types of antidepressants and side effects, as well
as to ﬁnd out about others’ experiences with them:
Years ago I kind of just accepted what I was given and
didn’t really ask any questions but now I know to kind of
do research on the internet and to you know, which web-
sites are good to look at and which ones are not too
good. (Esther, UKb, F, 31)
Others used internet forums where witnessing others’
experiences helped them appreciate their own experi-
ence better:
Ah I’ve also seen a lot of other people on the internet as
well that have been through far worse than me. They’ve
trialled different medications and I’ve been fortunate
that the medication I’ve been given hasn’t had any, to my
knowledge, any major effects. Because if something don’t
get ya something else will, something else will. ( Joshua,
Aus, M, 51)
The initial consultation
Getting to the doctor
Our participants had often felt depressed for a long
time, only seeing a doctor and being prescribed an anti-
depressant after reaching a crisis point. They often
described trying to ‘manage’ on their own, long before
seeking help. Some went to the general practitioner
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(GP) only after family and friends urged them to do so,
others because their behaviour was obviously affecting
other people. Charlotte (Aus, F, 51), for example, went
to her GP when her husband was threatening to leave
her. Both Scott’s (Aus, M, 46) and Spencer’s (UKb, M,
52) wives made them go to the doctor after they broke
down at work. It can be difﬁcult for people to recognise
the signs and symptoms of depression themselves, and
certainly, for our participants, there was not always
awareness that treatments for their ailments existed that
might help.
The consultation
Some people recalled very positive initial experiences of
concordant consultations involving shared decision-
making, including a good discussion about their views,
fears and apprehensions and previous experiences of
taking antidepressants. For these participants, being lis-
tened too and given sufﬁcient time and information was
universally recognised as positive and valuable, and key
to the trust and rapport established between them and
their health practitioner:
If she hadn’t been able to turn my thinking around in
that ﬁrst appointment in the way that she did, you know,
I’m not convinced I would have been motivated to take
the medication. And certainly, you know, knowing now
that it does take sort of four to six weeks to really start to
have an effect I might have—even if I had started taking
it—I may well have given up after two weeks, you know.
But her, her inﬂuence was powerful enough that, you
know, it changed everything about the way I was looking
at the illness and subsequently at myself…So she then
spent the time explaining about depression and different
causes and, and then the medications and all of that.
(Scott, Aus, M, 46)
These initial dialogues appear to be key to people
developing a sense of agency with respect to their
decision-making about taking antidepressants. If people
trusted and respected their doctor and felt guided and
informed, they also reported initiation of treatment as
less problematic. In these instances, people more
happily accepted the treatment option as suggested by
their doctors, which ﬁtted with their view of what treat-
ment was needed.
Nevertheless, many people whom we interviewed were
resistant to being prescribed antidepressants due to the
strong stigma attached to them:
The ﬁrst mention of medication and antidepressants.
And um I don’t think she’d even ﬁnished saying the
word before I said ‘not a chance.’ I said ‘do you know
who you’re talking to here? I’m a detective. I think—this
is—you can’t do that.’ And there was no way I, I’d enter-
tain um just the label of the drug. Just the term anti-
depressant to me was ah you just can’t hack it. Um and I
thought ‘well that’s what I think so everybody else
must think that.’ So I said ‘nup, not a chance.’ (Sean,
Aus, M, 39)
While ‘shared decision-making’ is increasingly valued
as a necessary part of clinical care in consultations with
GPs, we interviewed both younger and older people who
told us that this was not something they had encoun-
tered. Some older people in particular described
one-way conversations which involved them simply
acceding to their doctors wishes, saying they had always
believed that the ‘doctor knows best’. Malcolm, (UKb, M
2=72), for example, had taken an antidepressant most of
his adult life on the advice of his doctors. For him, the
overwhelming impact of his depressive symptoms meant
that not taking the treatment was not an option.
Others raised concerns about the way that their con-
sultations unfolded, particularly where they felt like
there was a lack of discussion and negotiation. Some
people believed they were completely excluded from the
decision-making:
Well, yeah, on her notes I think she wrote depressed and
I think she said to me, “I think you’re suffering with
depression and need antidepressants”…And she put me
on antidepressants straight away, and on sleeping
tablets as well I think. She didn’t even ask me! (Belinda,
UKa, F, 33)
Rosey (UKa, F, 40) described not being told the
reason for her antidepressant prescription and how she
had never been given an explanation of what they would
do, nor the side effects.
People typically linked their experiences with antide-
pressants to their interactions with doctors in their con-
sultations. Having a good relationship with a doctor was
an important indicator of whether people would discuss
their need for information about adverse effects. Others
mentioned that being able to talk to their doctor
enabled them to reﬂect on their difﬁculties, and to
better understand or reframe their experiences.
People described dissatisfaction with the doctor–
patient interaction in terms of lack of attention to or
acknowledgment of the patient and/or issues they may
be encountering or experience. Apparent dismissive
reactions or preoccupation with note taking or prescrip-
tion writing, and superﬁcial or glib responses from
doctors to patients were commonly described and
experienced as negative and disempowering. Examples
included thinking that the doctor did not communicate
well or, listen to them, did not spend enough time with
them, did not supply them with sufﬁciently up to date
information, or did not behave as if the patient had
expertise too:
I’m just thinking, ‘My God, you know, they [doctors]
don’t believe me,’ but that’s what I felt, they just don’t
have time to listen [about side-effects]. (Anne, UKa, F, 39)
Even more difﬁcult for patients was feeling that they
were being coerced into taking antidepressants, or that
they do not have a choice in the matter:
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This GP was particularly um insistent that I take her pre-
scription. And I had said, ‘no,’ I had said ‘no’ about
three times. In the end she said to me, ‘um I don’t know
what’s wrong with depressed people, why they always
refuse to take um my prescriptions. I think depressed
people like being depressed.’ I felt like she’d shamed me
into taking her um prescription. (Vanessa, Aus, F, 35)
Others were surprised and even frightened by some of
the things doctors said about what antidepressant taking
would mean for them in the future, for example, that it
would take a long time to get better, or that they would
be dependent on them for life.
Being prescribed an antidepressant
Many people were relieved to be diagnosed with depres-
sion and be prescribed an antidepressant:
Once that was done it was like such a relief because I
knew what was wrong and I could see there was now a
way of ﬁxing it. I have to say my father had depression a
few years ago so I knew that there was a ‘ﬁx’ because he
was recovered he got treatment and he got better which
helped me a lot. (Spencer, UKb, M, 52)
Being offered a prescription for an antidepressant
brought signiﬁcant relief, as it helped people to feel that
their symptoms were recognised as a legitimate illness. A
sense of agency and, in turn, empowerment often
accompanied the receipt of a prescription as people felt
they were being proactive, acknowledging they were
depressed, and beginning to ‘tackle the problem’:
I think the ﬁrst doctor I ever saw was absolutely fantastic.
You know, he noticed the signs, he asked the questions.
He diagnosed me, treated me, when the treatment didn’t
work so well, you know, we adjusted it and got me back
on track within a couple of months. (Nancy, Aus, F, 26)
There were, however, also less positive reactions. When
Tony (UKb) was ﬁrst prescribed an antidepressant he
said he felt it signiﬁed his depression as ‘ofﬁcial’, liken-
ing it to a defeat, as though he had ‘surrendered’.
Seeing it written in his notes felt, ‘almost like having a
criminal record’. It had affected the way he felt about
himself as he felt designated to a denigrated category;
now he was someone who was ‘mentally ill’. People said
they would prefer to ‘manage’ without antidepressants,
wanting to come off them as soon as possible, or that it
was important to them for there to be ‘an end in sight’.
They talked about preferring to be ‘in control’ of their
own emotions and saw antidepressants as a temporary
‘crutch’ to lean on rather than a permanent solution.
Sam (UKb, M, 31) had felt it was taking the ‘lazy’
option when he was ﬁrst prescribed an antidepressant,
and said it felt like avoiding responsibility for his own
well-being. Others saw taking antidepressant as signifying
either to themselves or others that they were a ‘failure’.
Those people who had not been prescribed an anti-
depressant straight away appreciated the time to think
about it:
I didn’t really want to go on medication but I thought
that I was at the point where I needed something to help
me. They were very, very good in that they didn’t just
immediately give me a prescription. Actually, we went
through the options of what kind of medication…what
they do, what they’re designed for. And they said that
they would rather monitor my situation before letting me
go onto them, which I think was very responsible of
them. I did eventually, because I wasn’t getting any
better, did go onto antidepressants. (Patrick, UKa, M, 30)
Taking an antidepressant for the first time
Even after deciding to start antidepressants, actually con-
templating swallowing the tablet for the ﬁrst time could
feel like a momentous occasion:
I Ieft them on my top shelf for ages and I just didn’t
want to take them because I was a bit confused as why I;
he’s prescribed me that after like a really short chat, just
me saying I was down and maybe at the time they were
handing them out left right and centre, I don’t know.
(George, UKb,M, 34)
Other participants wanted to ﬁnd out more informa-
tion before taking their ﬁrst tablet. In the absence of
information from their doctors:
He said go home and take these Prozac but as a person
with a scientiﬁc mind as myself, I look up Prozac, I didn’t
take any, because so many side effect, I was so worried.
I just threw it away, threw them away… (Phuong, Aus,
F, 59)
Maggie (UKb, F, 44) got her prescription dispensed
but took time to read through the information leaﬂet
before deciding whether or not to take the ﬁrst dose.
She worried that the antidepressant might make her feel
‘ﬂuffy’ or ‘out of control’:
Hilary (UKb, F, 28) spent a full week wondering
whether to take the antidepressant and had second
thoughts after reading an article online. She saw the GP
for a second chat before deciding whether to take it.
Others felt less autonomy in their encounter with health
professionals:
I thought if I can be seen to be compliant to treatment it
would make me less likely to be sectioned. (Tony, UKb,
M, 34)
Our ﬁndings indicate that people can also feel unsure
about what to expect once they take the antidepressant,
and that it can be difﬁcult to make decisions and think
things through when very ill with depression:
Obviously the medication does what the, what the medi-
cation does but if, if she, I went home and I was, I read
the thing and I was very scared too, and I took a tablet
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after—not straight away, a few weeks. I took a tablet, I
took a tablet and it sort of made me so sick I retched the
whole night in the toilet, just retching, and it made me
feel like I almost died… (Phuong, Aus, F, 59)
People were uncertain about how long it would take
for the antidepressant to take effect, the extent to which
it might help, and about what to expect in the ﬁrst few
weeks. They were concerned that it could make them
feel worse rather than better, and fretted over how long
they would need to take an antidepressant for. Others
did feel a lot worse, at least at ﬁrst, and often took the
antidepressants for ‘a little bit’ and then stopped:
And so I started taking the medicine, um and it was
amazing. In, within two hours I could feel different. I
felt, well, like there were side effects…there was my jaw
would shake, and I would feel really sick, but within two
hours I felt calm; that sort of anxiety wasn’t there so
much. I felt calm and tired, too tired. I slept for, you
know, like 12 hours straight and then I had to go work. It
was very difﬁcult to go to work. (Laura, Aus, F, 55)
Others felt they beneﬁtted in time, if not immediately:
One of the, one of the most striking things that struck
me the ﬁrst time I took antidepressants…is all of a
sudden you realise how much colour is, there is in the
world. But I think when I was depressed my, my percep-
tion of colour had diminished. (Craig, UKa, M 33)
Others variously described how they felt as spaced out,
controlled, drunk, completely ﬂattened and numb,
although not depressed any more:
The ﬁrst week of it I felt I’d been hit over the head with
a sledgehammer. I found it really hard to have my bear-
ings and, and ah cope. It was just the most bizarre feeling
but I hung in there and after about ten days it, that got
better. (Edith, Aus, F, 55)
For some just the fact that they were taking the anti-
depressant and doing something about their depression
helped:
Straight away when you start taking it you feel great
because somebody understands, somebody has listened
to what’s wrong with you because you’re in this bubble
the only way I can describe it is a bubble, the whole
world is going on around you and nobody seems to
understand you assume that nobody…it just takes a lot of
weight lifted off your shoulders that you’re starting medi-
cation and that you’re starting on the road to get
better… (Ellie, UKb, F, 30)
DISCUSSION AND IMPLICATIONS
The data from 108 interviews in both UK and Australia
demonstrate the issues that people have when they are
considering taking and starting to take antidepressants
and provide some guidance for health professionals
about how people feel and how to approach
consultations with them. The issues were similar across
the data sets and there were no apparent differences
between men and women’s experiences nor between
ethnic or cultural groups across the two countries. It was
not the intention of the analysis to compare countries or
time periods, as treatment for depression has not
changed substantially over the past decades since the
introduction of selective serotonin reuptake inhibitors
(SSRIs),21 nor are there notable differences between
treatments in the UK and Australia. Participants were
not asked speciﬁcally in interviews to comment at length
on the complex issues surrounding the start of antide-
pressants. Thus, many such references to start were
offered up spontaneously. While each study was found to
be informative on the topic, no one study covered these
issues thoroughly. However, combined in an analysis, it
was found that the nuance of the analysis was increased
substantially.
Many of these ﬁndings are similar to what have been
reported elsewhere although those studies were derived
from studies of adherence and compliance.14–16
Although, medical encounters are only part of what
inﬂuences antidepressant use. Once people have actu-
ally sought help from the GP, what happened at the
initial consultation was critical for participants in their
decisions to subsequently take their antidepressant or
not. It is important that doctors take into account
people’s beliefs about medicines in general and medi-
cines for treating mental health issues in particular.2 22 23
When doctors took patients’ beliefs and concerns about
medicines into account, participants in our sample
were much happier with their consultation and
prescription.23 24
Some people may have no qualms at all about taking
antidepressants and clearly perceive them as being no
different to other medicines. But even so, they may still
experience effects like feeling spaced out, numb and so
on difﬁcult to accept because they impact on their
persona.25 Others struggle with the idea of taking anti-
depressants because they think that they can or should
get better on their own. This is often compounded by
the well-documented added burden of stigma and fear
of dependency that antidepressants bring.9 15 25
Being offered a prescription for an antidepressant tells
people that their symptoms are recognised by their GPs
as an illness. It can be a relief to know that it might help
the person feel better and give them hope for the
future.24 Sometimes just being given a prescription can
help people feel more positive knowing that they are
being proactive, acknowledging they are depressed, and
beginning to ‘tackle the problem’. For other people, it is
hard to reconcile a pharmacological treatment with
their understanding of personal and social problems,
and even questioning of the depression diagnosis.
Regardless, taking antidepressants for the ﬁrst time can
be a particularly anxiety provoking time, and people
may reject the medicines at this time, particularly if they
feel unsupported.
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Side effects, especially on start of therapy, are another
major barrier that people need support with and infor-
mation about.3 26 Our data suggest that people do want
to know what to expect before they started taking an
antidepressant. They felt reassured when they were pro-
vided with information and told that they can try differ-
ent types of antidepressants if side effects were
intolerable. Some participants wondered whether
doctors were reluctant to give their patients too much
information about side effects to avoid alarming them. If
people do not realise or anticipate (or this was not
explained to them by their GPs) that it can take a while
to adjust to an antidepressant they may not recognise
new symptoms as side effects of their medicine. Most
people read the patient information leaﬂet, many
ﬁnding it confusing, and often frightening given the list
of possible side effects. Most people in the data set used
the internet as a source of information about particular
antidepressants, and what they found both in website
sand on discussion forums inﬂuenced their subsequent
decision-making. Conﬂicting congeries of information
found online may be bewildering and health profes-
sionals could help by directing people to credible
websites.
Studies have shown that around 40% of patients who
start treatment with antidepressants ﬁll only a single pre-
scription at the pharmacy, apparently not accepting
treatment and, as with other new medicines27 stop
taking them after 2 weeks.28–31 Our data clearly show
that once people have got their antidepressants from
the pharmacy they often struggle with actually taking the
ﬁrst dose. Importantly, there was a signiﬁcant silence in
the narratives around experiences at pharmacies, with
little mention of support when ﬁrst or subsequent pre-
scriptions were dispensed. Antidepressants would be a
valuable additional group of medicines to add to the
new medicines service that provides pharmacist support
for prescription of a new medicine.32
Paramount in our data is the importance that people
attach to being listened to, to have time spent with them
considering the issues involved, and being treated as an
individual. They wanted to be involved in decisions
about their treatment and to understand the evidence
for it. Having a good relationship with their doctor,
which included being good communication, meant that
they were more willing to trust the advice that was being
given. Typically they wanted the opportunity to see the
same person each time, so that their ‘story’ was familiar
to the doctor. Some people were amazed at the speed
with which they were diagnosed with depression and
offered a prescription for antidepressants. Those who
were given more time to consider whether or not to take
them were much more satisﬁed. People also valued
being given realistic expectations about side effects and
being told that they do not work straight away. Doctors
in Maxwell’s study25 found it hard to manage depression
solely using a chronic disease model and were worried
about medicalising problems of everyday living while
offering antidepressants was the single thing that they
could do for the women.
For those responsible for the primary care of people
experiencing depression, this approach to patient care is
considered apposite in facilitating shared decision-
making as opposed to more paternalistic approaches.33
As Greenhalgh et al34 explain, importantly, “real shared
decision-making is not the same as taking the patient
through a series of if-then decision options. Rather, it
involves ﬁnding out what matters to the patient—what is
at stake for them—and making judicious use of profes-
sional knowledge and status (to what extent, and in what
ways, does this person want to be ‘empowered’?) and
introducing research evidence in a way that informs a
dialogue about what best to do, how, and why.” This tai-
lored treatment to individual context and needs is con-
sistent with research that has shown that people have a
range of different responses both to diagnosis, treatment
options and explanations thereof, and involvement in
shared decision-making.34 35 For example, Fullagar and
O’Brien36 and Dummit37 found that neurochemical
explanations of depression often offer comfort and
reassurance to women experiencing emotional distress,
and safeguard their access to medical care. In contrast,
Givens et al38 found that older people were resistant to
both antidepressants and depression as a diagnosis
because of its status as a medical illness.
The value of the shift from paternalism to shared
decision-making tailored to individual needs has been well
documented.33 39–41 However, as Fosgerau and Davidsen42
observe, “an essential question remains as to whether the
requirements for shared decision making are actually met
in clinical encounters.” This is signiﬁcant because health
professionals are likely to encounter a patient population
with a wide range of experiences of taking antidepressants
that are often contingent on their interaction with health
professionals and the relational process of decision-
making at the time of prescribing.43 Indeed, as for many
participants in our study, Fosgerau and Davidsen42 found
that shared decision-making did not take place because
doctors did not explore patients’ perspectives in depth or
take their perspectives into consideration.
The concept of shared decision-making and privil-
eging of patient-centered care are perhaps especially
important given that antidepressants are notoriously dif-
ﬁcult for people to take.28–31 44 The people whom we
interviewed expressed strong views about the need to be
able to make informed decisions about their diagnoses
and medicines prior to starting treatment. If people’s
initial consultation experience was experienced as posi-
tive and they viewed antidepressants as essential to
getting better they gladly accepted treatment options as
suggested by their doctors. These people considered
medicines as an important means through which they
could gain a sense of having a ‘normal life’. For some
their ﬁrst experience with medicines was unpleasant.
Others were left still feeling concerned about whether
they actually needed to take medicines.
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Limitations
While our study contributes important information it
must be considered in the light of a number of study
limitations. Only people willing to talk about their
depression or taking antidepressants were interviewed
and many of the participants regarded themselves as
being in ‘recovery’, and so were doing relatively well.
While the study does not claim numerical representation
(this is not the purpose of maximum variation sam-
pling), our sample reveals a wide range of experience
and complexities about experiences of taking antide-
pressants in the UK and Australia. Full details about
individual’s prescribed medicines in this study were not
available as they were not originally collected.
CONCLUSION
This paper is the ﬁrst to explore in depth the existential
concerns of starting antidepressant use using multicoun-
try data across two decades. There were no notable dif-
ferences between the two data sets from the UK and the
Australian data set, save for greater use of internet in
the later studies. People need to feel supported by
health professionals when they start taking antidepres-
sants. Health professionals may be able to use these ﬁnd-
ings to better understand patients’ potential concerns
about starting antidepressants. Given the difﬁculties
encountered at initiation of antidepressant therapy,
healthcare professionals need to consider how they
structure their consultations and about the information
that they provide. These insights are key to providing
appropriate support for people starting antidepressants.
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